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SUMMARY
Mammalian iron homeostasis is regulated by the in-
teraction of the liver-produced peptide hepcidin
and its receptor, the iron transporter ferroportin.
Hepcidin binds to ferroportin resulting in degradation
of ferroportin and decreased cellular iron export.
We identify the hepcidin-binding domain (HBD) on
ferroportin and show that a synthetic 19 amino acid
peptide corresponding to the HBD recapitulates the
characteristics and specificity of hepcidin binding
to cell-surface ferroportin. The binding ofmammalian
hepcidin to ferroportin or the HBD shows an unusual
temperature dependency with an increased rate
of dissociation at temperatures below 15C. The
increased rate of dissociation is due to temperature-
dependent changes in hepcidin structure. In con-
trast, hepcidin from poikilothermic vertebrates,
such as fish or frogs, binds the HBD in a tempera-
ture-independent fashion. The affinity of hepcidin
for the HBD permits a rapid, sensitive assay of hepci-
din from all species and yields insights into the
evolution of hepcidin.
INTRODUCTION
Systemic iron homeostasis is dependent on the expression of
the liver peptide hormone hepcidin and its interaction with the
cell-surface iron transporter ferroportin (Fpn) (for review, see
Ganz and Nemeth, 2006). Fpn exports iron from cells to plasma
and is responsible for iron absorption from the intestine, recy-
cling of erythrocyte iron by macrophages, and as shown in
mice, maternal delivery of iron to the fetus (Donovan et al.,
2005). Transcription of hepcidin in hepatocytes is regulated by
a variety of stimuli including cytokines (TNF-a, IL-6), erythropoi-
etic activity, iron stores, and hypoxia (De Domenico et al.,
2007a). Once secreted, hepcidin binds to Fpn and induces its in-
ternalization and degradation (Nemeth et al., 2004). Binding of
hepcidin to Fpn leads to the phosphorylation of either of two ad-
jacent tyrosines in a cytosolic domain of Fpn, resulting in the
internalization of phosphorylated Fpn by coated pits (De Dome-
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hepcidin binding or subsequent phosphorylation of Fpn ablate
Fpn-hepcidin internalization (De Domenico et al., 2007b). The
resulting persistence of cell-surface Fpn leads to a phenotype
similar to classical hereditary hemochromatosis, a disorder as-
sociated with inappropriately low levels of hepcidin (De Dome-
nico et al., 2006b). The difficulty of producing useful anti-hepci-
din antibodies has made measurements of plasma hepcidin
problematic, although measurements have been made by
mass spectroscopy (Kemna et al., 2007; Murphy et al., 2007).
Here we report the identification of the hepcidin-binding domain
(HBD) on Fpn and show that a synthetic peptide corresponding
to the HBD can be used in a competitive assay to measure hep-
cidin concentrations in small volumes of biological fluids. Mam-
malian hepcidin does not bind to the HBD at low temperature,
whereas fish hepcidin binds to the HBD in a temperature-inde-
pendent manner. This difference in binding activity is correlated
with differences in antimicrobial activity and provides insight into
the evolution of vertebrate hepcidin.
RESULTS
Identification of the Hepcidin-Binding Site on Fpn
Most of the reported Fpn mutations that lead to hepatic paren-
chymal iron overload disease in humans do not affect hepcidin
binding (De Domenico et al., 2005). There are three Fpn muta-
tions, however, that show no measurable binding of hepcidin
(E.N., unpublished data). All three are missense mutations at
position C326 (C326Y/T/S). (The number of the amino acid is
based on its position in the full-length protein.) This residue is
in an extracellular loop, which is just distal to the predicted cyto-
solic loop containing the two adjacent tyrosines that are phos-
phorylated in response to hepcidin binding (De Domenico
et al., 2007b). We hypothesized that this extracellular loop con-
tained the HBD. To test this hypothesis, we synthesized a 19
amino acid peptide that corresponds to the sequence of the ex-
tracellular loop spanning amino acids 324 through 343 and
determined if this peptide could compete with cell-surface Fpn
for hepcidin binding. Incubation of HEK293TFpn-green fluores-
cent protein (GFP) cells with hepcidin for 1 hr or 24 hr resulted
in the internalization of cell-surface Fpn-GFP (Nemeth et al.,
2004), as shown in Figure 1A and quantified in Figure 1B.
Preincubation of equimolar amounts of the predicted HBD with
C
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The Hepcidin-Binding Site on FerroportinFigure 1. HBD Inhibits Binding of Hepcidin to Fpn
(A) HEK293TFpn-GFP cells were incubated with or without hepcidin (1 mg/ml) or with hepcidin that had been preincubated either with HBD, scrambled HBD, or
HBD with the C326Y mutation (HBD mutant). (The number of the amino acid is based on its position in the full-length protein.) The HBD peptides and hepcidin
were mixed at an equimolar ratio for 2 hr at 37C and then added to cells for 1 hr or 24 hr. Fpn internalization at 1 hr was analyzed by epifluorescence.
(B) The percentage of cells showing internalized Fpn-GFP at 1 hr and 24 hr was quantified. The data are reported as the standard error of the mean and were
determined by counting ten fields containing 20–30 cells/field.
(C) Peptides (HBD, scrambled HBD, or mutant C326Y HBD) were conjugated to agarose beads (I-HBD). 125I-hepcidin was added to I-HBD for 18 hr at 37C (black
bars) or 4C (gray bars). The beads were washed, and the amount of 125I-hepcidin bound to beads was determined as counts per minute (cpm).
(D) Specified concentrations of hepcidin (Hep25) or hepcidin containing a tyrosine residue (M21Y and Y-Hep25) were added to I-HBD for 1 hr prior to the addition
of 125I-hepcidin. The mixture was incubated for 18 hr at 37C, and the amount of 125I-hepcidin bound to beads was determined. The data are expressed as the
percentage 125I-hepcidin bound to I-HBD. All experiments were repeated a minimum of five times, and the error bars represent the standard error of the mean.
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Fpn-GFP. This was not due to inhibition of endocytosis, as the
amount of pinocytosed fluorescent dextran was similar in cells
incubated with or without HBD (data not shown). Preincubation
of hepcidin with a peptide containing the same amino acid com-
position as HBD but in a randomized sequence (HBD scramble)
had little effect on Fpn internalization, as did preincubation with
an Fpn peptide containing the C326Y mutation (HBD mutant).
To further characterize the interaction of the HBD with hepci-
din, the HBD peptide was conjugated to agarose beads
(I-HBD) and incubated with 125I-hepcidin at 37C. As shown pre-
viously, 125I-hepcidin was capable of inducing Fpn-GFP internal-
ization (Nemeth et al., 2004). When hepcidin or 125I-hepcidin was
preincubated with I-HBD, followed by removal of the I-HBD, the
remaining supernatant lost the ability to internalize Fpn-GFP,
indicating that I-HBD bound hepcidin (see Figure S1B online).
No loss of internalization activity was seen when 125I-hepcidin
was preincubated with beads containing either HBD scrambled
RECor C326Y HBD mutant (data not shown). These results indicate
that 125I-hepcidin interacts in a specific manner with the HBD
even when the HBD is immobilized. The use of 125I-hepcidin per-
mitted a quantitative assay of binding activity. 125I-hepcidin
bound only to I-HBD at 37C and not to the C326Y-HBD mutant
and showed severely reduced binding to the HBD scramble
(Figure 1C). Accordingly, no loss of internalization activity was
seen when 125I-hepcidin was preincubated with I-HBD at 4C
(Figure S1B). The binding of 125I-hepcidin to I-HBD could be
competed by simultaneous addition of hepcidin (Hep25). For
these experiments, we utilized a M21Y-substituted hepcidin to
generate a radioactive molecule. These data show that the
M21Y hepcidin binds with identical affinity (apparent Kd of ap-
proximately 200 nM) to native hepcidin (Figure 1D).
We took advantage of this assay to examine the importance of
amino acids surrounding C326 in Fpn. We synthesized different
HBDs in which alanine was substituted for specific amino acids
surrounding C326 (Figure 2A). We assayed the effect of thoseell Metabolism 8, 146–156, August 6, 2008 ª2008 Elsevier Inc. 147
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The Hepcidin-Binding Site on FerroportinFigure 2. Effect of Amino Acid Substitutions on the Binding of Hepcidin to the HBD and Cell-Surface Fpn
(A) HBDs containing amino acid substitutions (gray alanines A) were synthesized.
(B) The ability of modified HBD to bind 125I-hepcidin was assayed as described in Figure 1.
(C) Amino acid substitutions were generated in Fpn-GFP by site-specificmutagenesis as described in Experimental Procedures. Plasmids containing wild-type or
mutant Fpn-GFP were transiently transfected into HEK293T cells for 18–24 hr. The transfected cells were incubated with hepcidin (4 mg/ml) for 4 hr, and inter-
nalization of Fpn-GFP was assayed by epifluorescence microscopy.
(D) 125I-hepcidin was added to HEK293T cells expressing wild-type Fpn-GFP or mutant Fpn-GFP, and cell-associated radioactivity was measured. The expres-
sion of Fpn-GFP constructs was assessed by western-blot analysis using antibodies to Fpn with 25 mg of protein loaded per lane. The data are expressed as
percentage uptake in which binding to cells expressing wild-type Fpn-GFP was normalized to 100%. All experiments were repeated a minimum of five times,
and the error bars represent the standard error of the mean.
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to prevent hepcidin-mediated internalization of cell-surface
Fpn-GFP (Figure S2) and by examining the ability of the modified
HBD to bind hepcidin (Figure 2B). All alanine substitutions
affected the ability of the HBD to bind hepcidin. It was surprising,
however, that the relatively conservative change of A for I on res-
idue 327 significantly affectedbinding activity (Figures 2B andS2).
To examine the correlation between hepcidin binding to the
HBD and hepcidin binding to cell-surface Fpn-GFP, we gener-
ated the same alanine substitutions in Fpn-GFP and measured
hepcidin-mediated internalization and degradation as well as
the binding of 125I-hepcidin tomutant Fpn-GFP-expressing cells.
When transfected into HEK293T cells, all mutant Fpn-GFP con-
structs were expressed at the same level and were appropriately
targeted to the cell surface (Figure 2C). Addition of hepcidin led
to the internalization and degradation of wild-type Fpn-GFP, but
there was little internalization or degradation of Fpn(C326Y)-
RE148 Cell Metabolism 8, 146–156, August 6, 2008 ª2008 Elsevier IncGFP, Fpn(F324A)-GFP, Fpn(T328A)-GFP, and Fpn(324-328A)-
GFP. Hepcidin was able to partially induce the internalization/
degradation of Fpn(D325A)-GFP and Fpn(I327A)-GFP. Uptake
of 125I-hepcidin to mutant Fpn-GFP cells showed the same
pattern: no radioactivity associated with substitutions C326Y,
F324A, T328A, and 324-328A, and half-maximal radioactivity
was found on cells transfected with Fpn mutants D325A and
I327A (Figure 2D). It is noteworthy how well all of the assays
(internalization and quantitative hepcidin binding) for the cell-
surface mutants and the HBD mutants agree. These results
show that binding of hepcidin to the HBD faithfully reproduces
binding of hepcidin to cell-surface Fpn.
Binding of Hepcidin to theHBD Is Temperature Sensitive
Previously, we determined that hepcidin binding to Fpnwas tem-
perature dependent; binding was detected at 37C but not at
4C (Nemeth et al., 2004). Preincubation of HBD with hepcidin.
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The Hepcidin-Binding Site on FerroportinFigure 3. Dissociation of Mammalian Hepcidin-HBD Complexes Is Accelerated by Low Temperature
(A) A subsaturating concentration of 125I-hepcidin (200 nM) was incubated with I-HBD for 18 hr at the specified temperatures, and the amount of radioactivity
bound to beads was determined.
(B) 125I-hepcidin was added to I-HBD, and a complexwas allowed to form at 37C. The beadswere washed and incubatedwith excess nonradioactive hepcidin at
37C (closed circles) or 4C (open circles) for the specified times, and the amount of radioactivity bound to beads was determined. The data are expressed as
radioactivity at each time point relative to the amount bound at zero time.
(C) I-HBDwas incubated with different concentrations of NEM for 4 hr at 37C. The beads were washed, I25I-hepcidin was added, and the amount of radioactivity
bound to beads was determined (open circles). Alternatively, the I-HBD-125I-hepcidin complex was allowed to form at 37C. The beads were washed and then
incubated with the specified concentrations of NEM for 4 hr, and radioactivity bound to the beads was determined (closed circles). The data are expressed as the
amount of radioactivity at each time point relative to the amount of radioactivity bound to beads prior to NEM treatment. All experimentswere repeated aminimum
of five times, and the error bars represent the standard error of the mean.ET
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prevented the hepcidin-mediated internalization of Fpn-GFP,
whereas preincubation at 4C did not (Figure S1). Preincubation
of hepcidin and HBD was required, as simultaneous addition of
hepcidin and HBD to cells did not prevent internalization
of Fpn-GFP (data not shown). Examination of the binding of
125I-hepcidin to I-HBD as a function of temperature showed
that binding was decreased dramatically at temperatures below
15C (Figure 3A). The 125I-hepcidin-I-HBD complex was
extremely stable at 37C. In the presence of a largemolar excess
of nonradioactive hepcidin, there was little dissociation of pre-
formed 125I-hepcidin-I-HBD over a time course of 24 hr (closed
circles in Figure 3B). When the 125I-hepcidin-I-HBD complex
was shifted from 37C to 4C, 125I-hepcidin rapidly dissociated
R
Cfrom the I-HBD (open circles in Figure 3B). Treatment of HBD
with the alkylating agent N-ethylmaleimide (NEM) led to a loss
of 125I-hepcidin-binding activity (open circles in Figure 3C),
suggesting that the free cysteine in the HBD is required for
hepcidin binding. NEM added to a preformed 125I-hepcidin-
I-HBD complex at 37C did not result in dissociation of the
complex (closed circles Figure 3C). Since NEM inactivates the
binding activity of the HBD, we conclude that binding of hepcidin
to the HBD prevents access of NEM to the free cysteine in
the HBD.
Structural Changes in Hepcidin Affect HBD Binding
To define the mechanism of the temperature sensitivity of hepci-
din binding, we examined the properties of hepcidin and HBD byell Metabolism 8, 146–156, August 6, 2008 ª2008 Elsevier Inc. 149
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The Hepcidin-Binding Site on FerroportinFigure 4. Temperature-Dependent Changes in Mammalian Hepcidin Structure
(A) Human hepcidin (Hep), HBD, or an equimolar mixture of HBD and hepcidin were analyzed by CD at 37C and 4C from wavelength (l) 190 to 260. The insert
shows the effect of temperature on the CD spectrum of hepcidin measured at 210 nm.
(B) 125I-hepcidin was applied to a G-25 column, equilibrated, and eluted at 25C (black bars) or 4C (gray bars), and the amount of radioactivity in eluted fractions
was determined. The arrows represent the elution of molecular weight standards, insulin (5808 Da), and DBI (2150 Da). The elution of the standards was not
affected by temperature.
(C) The CD spectrum of Hep20 (100 mM) was measured at different temperatures. All experiments were repeated a minimum of five times, and the error bars
represent the standard error of the mean.
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spectrum characteristic of mostly b sheets with a small amount
of a-helical structure when measured at 20C or higher
(Figure 4A), a result consistent with published studies (Nemeth
et al., 2006). An equimolar mixture of HBD and hepcidin had
a CD spectrum similar to that of hepcidin alone. There was a dra-
matic change in theCD spectrumat 4C, showing little secondary
structure for the hepcidin-HBD mixture or for hepcidin alone.
These results indicate that thestructureof hepcidin is temperature
sensitive. We determined that the change in hepcidin structure
occurs between 15C and 10C (small insert in Figure 4A), similar
to the temperature where hepcidin no longer binds to the HBD.
The temperature-dependent change in hepcidin structure
resulted in a change in the multimerization state of hepcidin.
Previous studies indicated that hepcidin formed multimers in
a concentration-dependent manner (Hunter et al., 2002). At the
RE150 Cell Metabolism 8, 146–156, August 6, 2008 ª2008 Elsevier Incconcentrations employed in this study and at 25C, hepcidin is
a monomer, as shown by size-exclusion chromatography (Fig-
ure 4B). When the same preparation of hepcidin was incubated
at 4C and then applied to size-exclusion chromatography, hep-
cidin eluted predominantly as a dimer.
Derivatives of hepcidin lacking the first five amino acids
(Hep20) do not bind to Fpn (Nemeth et al., 2004) nor do they
bind to HBD (data not shown). CD analysis of Hep20 showed
a spectrum identical to that of hepcidin when assayed at 25C
(Nemeth et al., 2006). In contrast to hepcidin, the CD spectrum
of Hep20 did not change when assayed at 4C (Figure 4C), nor
did Hep20 show a temperature-dependent multimerization
when assayed by size-exclusion chromatography (data not
shown). These results suggest that the temperature-dependent
changes in hepcidin structure require the presence of the amino
terminal domain of hepcidin..
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The Hepcidin-Binding Site on FerroportinFigure 5. Alignment of Vertebrate Fpn-HBD and Hepcidin and the Effect of Temperature on Hepcidin Activity
(A) Alignment of HBD sequence from homeothermic (warm blooded) and poikilothermic (cold blooded) vertebrates. The arrows denote the location of the tyro-
sines that are phosphorylated upon hepcidin binding and cysteine 326, which when mutated leads to hepcidin resistance and ferroportin-linked hemochroma-
tosis. The ‘‘*’’ represents identity and the ‘‘:’’ represents similarity. The accession numbers are listed next to the sequence.
(B) Alignment of hepcidin sequence from mammals, fish, and Xenopus laevis.
(C) I-HBD was incubated with human or zebrafish hepcidin or with serum from Salmo trutta, Pungitius pungitius, or Xenopus laevis for 12 hr at 37C. The beads
werewashed three times, and 125I-hepcidin was added for 1 hr at 37C. The amount of radioactivity boundwas determined and compared to that bound to I-HBD,
which had been incubated with 125I-hepcidin for 1 hr (black bars). An aliquot of I-HBD that had been incubated with hepcidin or sera was washed and then
incubated at 4C for 12 hr. Following washing, 125I-hepcidin was added at 37C, and the amount of radioactivity was determined after 1 hr (gray bars).
(D)E. coli, grown in LBbroth, were incubatedwith 30 mMof hepcidin (Hep25), Hep20, or zebrafish hepcidin (ZHep25) at 37C (black bars) or 4C (gray bars) for 4 hr.
Aliquots of bacteria were plated on LB and incubated at 37C for 12 hr, and the number of colonies was determined. The data are expressed as the percentage of
colonies observed in the absence of hepcidin. All experiments were repeated aminimumof five times, and the error bars represent the standard error of themean.TR
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DHepcidin from Poikilotherms Does Not Show
Temperature-Sensitive Binding to the HBD
Core temperatures below 20C are unusual among mammals,
and it is unclear if low temperatures have any specific effect
on iron metabolism. The core temperature of hibernating
mammals (such as ground squirrels) can reach 4C. At these
temperatures, metabolic activity is severely reduced. Many poi-
kilothermic vertebrates such as fish, however, routinely live at
temperatures below 15C, and we questioned whether fish hep-
cidin would show temperature-sensitive binding to HBD. The
sequence of the Fpn HBD in poikilothermic and homeothermic
vertebrates shows near identity (Figure 5A). The few instances
of sequence variation are highly conserved and are not consis-
tent features of either poikilotherms or homeotherms. Fish
appear to have multiple hepcidin genes, which encode hepcidin
peptides that are 25, 22, and 20 amino acids in length (for review,
see Shi and Camus, 2006). In contrast to the HBD, the sequence
of the 25 amino acid form of hepcidin shows consistent differ-
ences between poikilotherms and homeotherms (Shi and
RECCamus, 2006). The carboxyl terminal amino acid and the first
five amino terminal amino acids are different for the two groups
(Figure 5B). Zebrafish hepcidin binds to mammalian Fpn, induc-
ing its internalization and degradation (Nemeth et al., 2006).
Chemically synthesized zebrafish hepcidin bound to the HBD
at 37C, and similar-to-human hepcidin showed a slow rate of
dissociation at 37C. Unlike human hepcidin, however, zebrafish
hepcidin did not dissociate from the HBD at 4C (Figure 5C).
Similar results were obtained using sera of Salmo trutta (brown
trout) or Pungitius pungitius (Alaskan nine-spine stickleback),
fish that live at temperatures below 10C. Sera from these fish
inhibited the binding of 125I-hepcidin to the I-HBD at 37C.
When the serum-incubated I-HBDwas placed at 4C, no binding
activity was recovered when assayed at 37C. This result sug-
gests that hepcidin present in fish serum bound to the I-HBD
but did not dissociate at 4C. Serum from the amphibian Xeno-
pus laevis also bound to the HBD in a temperature-independent
fashion, suggesting that Hep25 from poikilothermic vertebrates
may behave similarly.ell Metabolism 8, 146–156, August 6, 2008 ª2008 Elsevier Inc. 151
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The Hepcidin-Binding Site on FerroportinFigure 6. Determination of Hepcidin Concentrations in Human and Mouse Sera
(A) Samples (25 mL) from pooled human sera were incubated with I-HBD and a known concentration of 125I-hepcidin for 18 hr at 37C. The beads were then
washed, and the amount of radioactivity was determined. Serum hepcidin levels were calculated relative to a standard curve constructed using chemically
synthesized human hepcidin. For these and the data described below, each sample was measured in triplicate, and the error bars represent the standard error
of the mean.
(B) Hepcidin levels were determined in sera obtained from normal individuals of defined age and gender or in serumobtained from a female patient diagnosedwith
JH due to mutations in the HJV gene as described in (A).
(C) Hepcidin levels in sera obtained from wild-type mice (C57BL/6), mice homozygous (HAMP/), or heterozygous (HAMP+/) for a targeted gene deletion in
HAMP, or mice that were homozygous for a targeted gene deletion in HFE were determined as described in (A).
(D) C3H/HeJ mice were injected intraperitoneally with LPS, serum was obtained from the mice 12 hr later, and hepcidin concentration was determined as
described in (A). The data are expressed as percentage of normal in which hepcidin levels in the absence of LPS is 100%. All experiments were repeated a min-
imum of five times, and the error bars represent the standard error of the mean.
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et al., 2001), and we questioned whether hepcidin antimicrobial
activity is affected by temperature. Human hepcidin (Hep25)
showed temperature-sensitive behavior in its ability to bind to
Escherichia coli, as measured by binding of 125I-hepcidin to
E. coli (data not shown) and by its antimicrobial activity
(Figure 5D). The antimicrobial activity of Human Hep20 was
unaffected by temperature. In contrast to human hepcidin,
zebrafish hepcidin (ZHep25) had severely reduced antimicrobial
activity against E. coli at either temperature. These results sug-
gest that the multiple hepcidin genes found in poikilothermic
vertebrates may have evolved to diversify the iron regulatory
and antimicrobial activities.
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We recognized that binding of 125I-hepcidin to I-HBD could be
used to assay hepcidin concentrations in biological fluids. We
assayed the ability of human serum to compete with 125I-hepci-
din for binding to the I-HBD. We determined the concentration of
hepcidin in serum and showed a linear relationship with serum
volume (Figure 6A). A known quantity of chemically synthesized
hepcidin added to serum was quantitatively recovered (data not
shown). Repeated measurements of hepcidin in sera showed
less than 5.0% variation. We did observe a decrement (10%) in
binding activity upon freezing and thawing, but the decrement
was independent of absolute hepcidin level. Measurement of
hepcidin in sera from a population of normal individuals showed.
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The Hepcidin-Binding Site on FerroportinFigure 7. Predicted Topology of Fpn Showing the Position of Mutations that Lead to Hepcidin Resistance
The structure of Fpn is based on the study of Liu et al., 2005. We have added the locations of known human mutations that result in hepcidin-resistant iron over-
load disease S338R (Wallace et al., 2007), C326S (Sham et al., 2005), N144H (Njajou et al., 2002), Q182H (Hetet et al., 2003), and G80S (De Domenico et al.,
2006a). We have also noted the positions of introduced amino acid substitutions that affect hepcidin binding and Fpn internalization (Y302 and Y303) and deg-
radation (K253A) (De Domenico et al., 2007b).
TE
DAgender-associated differences: males had, in general, higherhepcidin levels than females (Figure 6B). Serum hepcidin levelsalso showed an age-dependent increase, which is consistentwith age-dependent increases in iron burden (Casale et al.,1981). Sera from a population of normal females (20–30) showedan average of 50 ng/ml hepcidin, while an age-matched individ-
ual with juvenile hemochromatosis (JH), with knownmutations in
the hemojuvelin gene (HJV) (Huang et al., 2004), showed very low
levels of hepcidin.
The conservation of hepcidin and Fpn sequences also permit-
ted the assay of hepcidin levels in other vertebrates. We mea-
sured the levels of hepcidin in sera obtained from wild-type
mice C57BL/6, mice homozygous (HAMP/), and heterozygous
(HAMP+/) for a targeted deletion in the hepcidin gene (HAMP)
(Lesbordes-Brion et al., 2006), or mice homozygous (Hfe/)
for a targeted deletion in theHFE gene, a gene implicated in hep-
cidin transcription (Levy et al., 1999) (Figure 6C). Sera obtained
from wild-type C57BL/6 mice contained approximately 80–100
ng/ml hepcidin. Serum from HAMP/ mice had essentially
undetectable levels of hepcidin, while HAMP+/ mice showed
70% of normal values. Hfe/mice showed lower levels of hep-
cidin than the HAMP+/ mice. Hepcidin expression increases in
response to inflammatory stimuli (Nicolas et al., 2002); Injection
of lipopolysaccharide (LPS) into C3H/HeJ mice indeed resulted
in increased serum hepcidin (Figure 6D). These data demon-
strate that I-HBD can be used to assay hepcidin levels in biolog-
ical fluids.
DISCUSSION
The identification of the HBD elucidates many features regarding
the physiology of hepcidin and Fpn. Binding of hepcidin to Fpn
leads to the internalization and degradation of Fpn, preventing
cellular iron export, and it is amajor controlling factor of systemic
RE
TRCiron homeostasis (Nemeth et al., 2004). The HBD is in the extra-
cellular loop of Fpn adjacent to the cytosolic loop containing the
two tyrosines required to signal internalization (Figure 7). The fig-
ure shows human mutations that lead to hepcidin resistance,
which can be ascribed to either an inability to bind hepcidin or
an inability to respond to bound hepcidin. There are other human
mutations in ferroportin that lead to defective iron export, most
commonly because themutant ferroportins are not appropriately
trafficked to the cell surface (for review, see De Domenico et al.,
2006b and Liu et al., 2005). To date, only mutations in the HBD
have been identified to prevent hepcidin binding. The HBD is
separated from the cytosolic loop containing the phosphoryla-
tion site by a single transmembrane domain. The juxtaposition
of these two domains suggests that even small changes in pro-
tein conformation resulting from binding of hepcidin to Fpnmight
lead to a change in the conformation of the cytosolic loopmaking
the tyrosines accessible to a protein kinase. Three independent
mutations in cysteine 326 have been identified in human patients
with hepcidin-resistant iron overload disease (Drakesmith et al.,
2005; Sham et al., 2005, and E.N., unpublished data). Recently,
themutation S338R—which is in the HBD—has been reported to
lead to hepcidin-resistant iron overload disease (Wallace et al.,
2007). As shown in this study, amino acid substitutions
surrounding cysteine 326 also prevent hepcidin binding. This
result suggests that a number of mutations can lead to a func-
tional iron transporter that is correctly targeted to the cell surface
but is unable to bind and respond to hepcidin.
Mammalian hepcidin binds to Fpn (Nemeth et al., 2004) or the
I-HBD in a temperature-dependent manner. We initially thought
that the lack of binding of hepcidin to Fpn-GFP-expressing cells
at low temperature reflected weak binding and that the more
stable association of hepcidin with cells at 37C reflected the
internalization of the hepcidin-Fpn complex. Our data, how-
ever, shows that the lack of binding of hepcidin to Fpn at low
Cell Metabolism 8, 146–156, August 6, 2008 ª2008 Elsevier Inc. 153
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the Fpn-hepcidin complex due to a temperature- sensitive
change in hepcidin structure. The structure of human hepcidin is
suggested to be a hairpin formed from a distorted antiparallel b
sheet stabilized by disulfide bonds, and it is predicted to be
amphipathic, showing both a hydrophilic and hydrophobic sur-
face (Hunter et al., 2002). Human hepcidin structure is markedly
altered at low temperature where hepcidin forms dimers. The
change in hepcidin structure is dependent on the amino terminus
of hepcidin, as Hep20 does not change its structure or form di-
mers at low temperature. The change in structure affects its
binding to bacteria at low temperature. The five amino terminal
amino acids of hepcidin were also previously shown to be critical
for binding of hepcidin to Fpn (Nemeth et al., 2006), as Hep20
does not bind to Fpn and, as shown here, does not bind to the
I-HBD. The CD structure of Hep20 does not change at low tem-
perature, and the antimicrobial activity of Hep20 is not affected
by low-temperature exposure.
Binding of hepcidin to the HBD faithfully reflects binding of
hepcidin to cell-surface Fpn. Truncated forms of hepcidin that
do not bind to Fpn do not bind to the HBD. Mutations in Fpn
and in the HBD affect binding to hepcidin in an identical manner.
We have presented data showing that Fpn is a dimer (De Dome-
nico et al., 2006a, 2005). The binding of hepcidin to the HBD,
which is monomeric, and to Fpn, which is dimeric, is similar.
This suggests that dimer formation does not affect hepcidin-
binding activity. The one difference we have observed in hep-
cidin binding is that binding of hepcidin to cell-surface Fpn has
a kinetic advantage over binding to the HBD. At 37C, the rate
of dissociation of mammalian hepcidin from the HBD is ex-
tremely slow; yet, simultaneous addition of the HBD and hepci-
din to cells did not prevent hepcidin from binding to cell-surface
Fpn. Our explanation for this observation is that the ‘‘tethering’’
of the HBD to cell surfaces provides a kinetic advantage in the
association constant of binding. A precedent for the kinetic
advantage of membrane tethering was shown years ago through
studies of cytochrome b5 (Enoch et al., 1977).
There is a high degree of conservation among vertebrate hep-
cidins from both homeothermic and poikilothermic species.
Most mammals have one functional hepcidin gene, in contrast
to fish, which have multiple hepcidin genes (Shi and Camus,
2006). Fish appear to have at least one hepcidin gene that
encodes a mature form of 25 amino acids, whereas many of
the other genes encode mature hepcidins of less than 25 amino
acids. Based on studies of zebrafish and mammalian hepcidins,
these smaller hepcidin forms should not bind to Fpn. Most fish
hepcidins have a similar amino terminus, and hepcidin from trop-
ical (zebrafish) and cold water (brown trout, stickleback) fish
occupy the HBD at both high and low temperatures. The binding
of fish hepcidin to Fpn regardless of temperature indicates that it
regulates iron metabolism.
There are many studies on the expression of fish hepcidins,
but there is only limited evidence for the antimicrobial activity
for the different-sized hepcidins (Lauth et al., 2005; Shike et al.,
2002). As shown here, the zebrafish 25 amino acid hepcidin
has little antibacterial activity against E. coli. A chemically syn-
thesized 25 amino acid hepcidin (TH2-3) from the fish Tilapia
had antimicrobial activity against some bacteria, whereas a 23
amino acid Tilapia hepcidin (TH1-5) had antimicrobial activity
RE
TR
A154 Cell Metabolism 8, 146–156, August 6, 2008 ª2008 Elsevier Inc.against different bacteria (Huang et al., 2007). A third putative Ti-
lapia hepcidin (TH2-2) had no antimicrobial activity against the
tested bacteria. Together, these results suggest that mammalian
hepcidin has both iron regulatory and antimicrobial activity, while
fish hepcidin genes have evolved to separate these two func-
tions. A recent study has shown that fish hepcidins, in contrast
to mammalian hepcidin, have been under increased selective
pressure, as shown by the presence of multiple hepcidin genes
and by increased mutations in nonsynonymous codons (Padhi
and Verghese, 2007). Mammalian serum only appears to contain
the mature 25 amino acid form of hepcidin, but 22 and 20 amino
acid hepcidins are found in urine (Park et al., 2001). It had been
noted that the 20 amino acid hepcidin had greater antimicrobial
activity than the 25 amino acid form (Park et al., 2001). We con-
firmed this observation using E. coli.We suggest that the gener-
ation of the smaller forms may not reflect the catabolism of
hepcidin but rather the generation of a more potent antibacterial
hepcidin.
Finally, our data indicate that the I-HBD can be used to assay
hepcidin in biological fluids. The values we report are similar to
the values reported for the measurement of hepcidin in mouse
serum using mass spectroscopy (Murphy et al., 2007). The
values we obtained for the average concentration of human hep-
cidin in serum (55–70 ng/ml), however, are higher than those
reported for human serum by the mass-spectroscopy measure-
ments (Murphy et al., 2007; Tomosugi et al., 2006). Human and
mouse hepcidin are nearly identical, as are human and mouse
Fpn. It is unclear why the steady concentration of serum hepcidin
in mouse and human might be different. Our data indicate that
the steady-state levels of human and mouse hepcidin are fairly
similar. The HBD assay detects biologically active (with respect
to Fpn binding) hepcidin. It does not detect hepcidins that do
not bind to Fpn, such as Hep20. The HBD assay does not detect
urinary hepcidin. The inability to detect urinary hepcidin does not
result from an interference of urine with the assay, as the assay
can readily measure hepcidin added to human urine (data not
shown). We believe that hepcidin present in urine is not biologi-
cally identical to serum hepcidin. Support for this view comes
from a mass-spectroscopic analysis, which suggests the 25
amino acid form of hepcidin present in human urine has a lower
molecular mass than serum hepcidin (Kemna et al., 2005).
We present data showing that the HBD assay can readily de-
tect variations in serum hepcidin levels due tomutations in genes
known to affect hepcidin levels (HAMP), mutations in other
genes involved in iron metabolism (HFE), or LPS stimulation.
It is interesting to note that mice heterozygous for a deletion in
HAMP only show a 30% reduction in serum hepcidin, suggesting
that some allelic compensation might be occurring. This result is
consistent with the relatively normal iron levels and phenotype
found in HAMP+/ mice. Most mammals have one hepcidin
gene, while mice have a second highly homologous gene termed
HAMP2 (Pigeon et al., 2001). The expression of both HAMP1
andHAMP2were regulated by iron (Ilyin et al., 2003). Expression
of HAMP2 as a transgene had no effect on iron metabolism (Lou
et al., 2004), although mRNA levels for HAMP2 are induced by
inflammatory stimuli. The observation that mice with a targeted
deletion inHAMP have essentially no Fpn-binding activity in their
sera indicate that the HAMP2 protein does not interact with
Fpn, which explains its lack of effect on iron metabolism. The
CT
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The Hepcidin-Binding Site on Ferroportinsensitivity of the I-HBD hepcidin assay offers a facile approach to
determining hepcidin levels in serum as well as other biological
fluids. As demonstrated here, the evolutionary conservation of
the HBD permits measurements of hepcidin in the serum of all
vertebrates.
EXPERIMENTAL PROCEDURES
Cells and Media
HEK293T Fpn, a stable cell line in which Fpn-GFP expression is regulated by
the ecdysone promoter, was described previously (Nemeth et al., 2004).
Generation of Fpn Constructs
All human-Fpnmutationswere generated in pFpn-EGFP-N1 by using theQuik-
Change Site-Directed Mutagenesis Kit (Stratagene) amplified in E. coli, and it
was sequence verified before transfecting into mammalian cells, as described
in De Domenico et al., 2005.
Peptide Synthesis
Peptides corresponding to wild-type and mutant HBDs were synthesized at
the DNA/Peptide Core Facility, University of Utah, Salt Lake City, Utah. To in-
crease solubility, the peptides were synthesized with two arginines added at
the amino and carboxyl termini. The arginines did not affect the specificity,
temperature dependence, or affinity of the HBD for hepcidin. Human and
zebrafish hepcidin were prepared as described previously (Nemeth et al.,
2006). The sequence of the HBD is RR-FDCITTGYAYTQGLSGSILS-RR. The
sequence of the scrambled HBD is RR-ILSLFDAYCTGTQITGSGSY-RR. The
sequence of the C326Y mutant is RR-FDYITTGYAYTQGLSGSILS-RR.
Peptide Immobilization and Hepcidin-Competition Assay
HBD peptides were immobilized by covalently linking them to agarose beads
using AminoLink Plus Immobilization Kit (Pierce) according to the manufac-
turer’s instructions (1.0 mg of Fpn peptide per 2.0 ml of amino-link beads).
To measure hepcidin concentrations in biological fluids, samples were mixed
with a defined concentration of 125I-hepcidin and then added to HBD-conju-
gated beads. The samples were incubated at 37C or 4C for 12–18 hr. The
beads were washedmultiple times with phosphate buffered saline (PBS) to re-
move unbound 125I-hepcidin by centrifugation for 2 minutes at 850 3 g. The
fluid was removed, and the radioactivity bound to beads was determined by
gamma counting (Perkin/Elmer).
CD Spectroscopy
CD spectra (200–250 nm) of 100 mM hepcidin, hepcidin (Hep20, which lacks
the five amino terminal residues), and HBD in 50 mM sodium phosphate buffer
(pH 7.2) were recorded on an AVIV 62DS spectrometer (AVIV, Lakewood, NJ).
Samples were scanned at various temperatures (37C, 25C, 15C, 10C, and
4C) using a 1.0mmpath-length quartz cell (Starna Cells, CA). Before analysis,
spectra were baseline corrected by subtracting spectra of sample-free buffer
solution from the peptide-containing sample.
Other Procedures
Hepcidin with an M21Y substitution was synthesized, iodinated, and used in
binding assays as described (Nemeth et al., 2004). For gel-filtration chroma-
tography, 125I-hepcidin was applied to a G-25 superfine column (Amersham
Pharmacia) equilibrated in PBS. The column was calibrated using insulin
(5808 Da, Sigma), diazepam-binding inhibitor (DBI) fragment 51–70 human
(2150 Da, Sigma), and neurotensin (1672 Da, Sigma) as standards. Fractions
(200 mL) were collected and analyzed for 125I-hepcidin by gamma counting
(Perkin/Elmer), and SDS-PAGE analysis followed by Coomassie blue staining
(Pierce) for standards. The antibacterial activity of different forms of hepcidin
was tested for antimicrobial activity against E. coli (DH5a). Hepcidin was
added to a final concentration of 30 mM at 37C and 4C to bacterial cultures
grown in LB broth. The cultures were incubated with constant shaking for 4 hr
at either 4C or 37C. The cells were washed and aliquots were plated on LB
plates and incubated at 37C for measurement of colony-forming units.
All animal studies were approved by the Animal Research Committee at the
University of Utah. C3H/HeJ mice were injected with LPS (Sigma) and sacri-
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ACficed 10 hr later. Animals were euthanized, and blood was collected by cardiac
puncture. Mouse sera were collected in accordance with the Institutional
Animal Care and Use Committee protocols. Human sera were obtained
according to protocols approved by the University of Utah Institutional Review
Board and in accordance with the Declaration of Helsinki with informed con-
sent for samples obtained from all subjects. Sera were obtained fromPungitius
pungitius byDr. Michael Shapiro (University of Utah) and fromSalmo trutta har-
vested on the Middle Provo River using a 22 blue-winged olive, according to
the rules of the Utah Department of Wild Life. Protein concentrations were
measured using the BCA assay (Pierce, Rockford, IL). Western-blot analysis
was performed as described previously by using mouse rabbit anti-Fpn
(1:1000) followed by peroxidase-conjugated goat anti-rabbit IgG (1:12,500,
Jackson ImmunoResearch). Microscopic analysis was carried out using an
Olympus BX51 microscope (Olympus, Tokyo, Japan). Images were acquired
using Picture Frame 2.5 software (Olympus America, East Muskogee, OK).
All experiments were repeated a minimum of five times, and error bars repre-
sent standard error of the mean.
SUPPLEMENTAL DATA
Supplemental Data include two figures and can be found online at http://www.
cellmetabolism.org/cgi/content/full/8/2/146/DC1/.
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